Eye injection shows promise for Diabetes-Related vision loss

NCT ID NCT04597918

Completed Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called faricimab (VABYSMO) in people with diabetic macular edema, a condition where diabetes causes fluid buildup in the center of the retina, leading to vision loss. Participants receive injections of faricimab into the eye every four weeks. The goal is to see how the drug affects vision and eye structure, and to find biological markers that might predict who benefits most.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: faricimab (VABYSMO)
What this could lead to: If successful, this could help identify which patients with diabetic macular edema respond best to faricimab, potentially leading to more personalized treatment.
What could go wrong: This is an early-phase, single-arm study with no comparison group, so results may not confirm effectiveness. The treatment involves regular eye injections, which carry risks like infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic macular edema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC MACULAR EDEMA

Contacts and locations

Locations

Austin Research Center for Retina

Austin, Texas, 78705, United States
Bascom Palmer Eye Institute

Naples, Florida, 34103, United States
Centro Oftalmologico Dr. Charles S.A.

Capital Federal, C1116, Argentina
Charles Retina Institute

Germantown, Tennessee, 38138, United States
Cumberland Valley Retina PC

Hagerstown, Maryland, 21740, United States
Gloucestershire Hospitals NHS Foundation Trust

Gloucestershire, GL1 3NN, United Kingdom
Irccs Ospedale San Raffaele

Milan, Lombardy, 20132, Italy
Kings College Hospital

London, SE5 9RS, United Kingdom
Long Is. Vitreoretinal Consult

Great Neck, New York, 11021, United States
Northwestern Medical Group/Northwestern University

Chicago, Illinois, 60611, United States
Oftalmos

Capital Federal, C1120AAN, Argentina
Ospedale San Giuseppe

Milan, Lombardy, 20123, Italy
Raj K. Maturi, MD PC

Indianapolis, Indiana, 46290, United States
Retina Consultants of Texas

Houston, Texas, 77030, United States
Retina Institute of Ottawa

Ottawa, Ontario, K2B 7E9, Canada
Retina Res Institute of Texas

Abilene, Texas, 79606, United States
Strategic Clinical Research Group, LLC

Willow Park, Texas, 76087, United States
Sunderland Eye Infirmary

Sunderland, SR2 9HP, United Kingdom
The Retina Institute

St Louis, Missouri, 63128, United States
Universitatsklinikum Tubingen

Tübingen, 72076, Germany
University Retina and Macula Associates, PC

Oak Forest, Illinois, 60452, United States
Vitreous Retina Macula Specialists of Toronto

Etobicoke, Ontario, M8X 2X3, Canada
Wojskowy Instytut Medyczny - Panstwowy Instytut Badawczy

Warsaw, 04-141, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.